β—阻滞剂治疗梗阻型肥厚性心肌病已有10余年的历史。然而,长期随访发现其疗效并不十分理想。实验发现用钙拮抗剂后,可以避免某种类型心肌病的发生,例如叙利亚仓鼠的遗传性心肌病和红比霉素引起的心肌病等。实验性心肌病与人类心肌病虽有所不同,但两者的机理可能相似,钙离子可能在其中起有重要作用。即使到达疾病的严重阶段,梗阻型肥厚性心肌病患者的左心室收缩力仍是非常强烈,对儿茶酚胺和洋地黄极为敏感,这都可能和细胞内钙的增高有关。本文报道用钙抑制剂异搏停治疗梗阻型肥厚性心肌病的临床试用结果。方法:22例19～44岁的梗阻型肥厚性心肌病 β-blocker therapy for obstructive hypertrophic cardiomyopathy has more than 10 years of history. However, long-term follow-up found that its efficacy is not very satisfactory. Experiments found that with calcium antagonists, you can avoid the occurrence of some types of cardiomyopathy, such as Syrian hamster hereditary cardiomyopathy and cardiotrophin-induced cardiomyopathy and so on. Experimental cardiomyopathy and human cardiomyopathy are different, but the mechanism of the two may be similar, calcium ions may play an important role in them. Left ventricular contractile force is still very strong in patients with obstructive hypertrophic cardiomyopathy and is extremely sensitive to catecholamines and digitalis even after reaching a severe stage of the disease, which may be related to an increase in intracellular calcium. This article reports the use of calcium inhibitor verapamil in the treatment of obstructive hypertrophic cardiomyopathy clinical trial results. Methods: Twenty-two patients with obstructive hypertrophic cardiomyopathy aged 19-44 years old were enrolled